Assignee
EMPROS PHARMA AB
SE·2 granted patents·3 pending applications·0 citations·filing 2015–2024
Top patents by PatentIndex Score
5 records- 0164US2024342096A1Modified release composition of orlistat and acarbose for the treatment of obesity and related metabolic disordersEMPROS PHARMA AB·Filed 2024·Application pending·0 cites
- 0252US11975105B2Modified release composition of orlistat and acarbose for the treatment of obesity and related metabolic disordersEMPROS PHARMA AB·Filed 2020·Granted May 7, 2024·0 cites·15 claims
- 0342US2025127752A1Reduced rebound effects in subjects treated for overweight or obesityEMPROS PHARMA AB·Filed 2022·Application pending·0 cites
- 0442US2024226024A1Synergistic effects on weight loss, improved quality of life and reduced gastro-intestinal side effects with a composition of orlistat and acarboseEMPROS PHARMA AB·Filed 2022·Application pending·0 cites
- 0537US10561617B2Modified release composition of orlistat and acarbose for the treatment of obesity and related metabolic disordersEMPROS PHARMA AB·Filed 2015·Granted Feb 18, 2020·0 cites·27 claims
Join the waitlist — get patent alerts
Get an alert when EMPROS PHARMA AB files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →